Drug profile · INN
belinostat
BELEODAQ
belinostat (BELEODAQ) is a histone deacetylase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — belinostat
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 1
- Programs
- 1
- Data quality
- 0.84
Quick answer
belinostat (BELEODAQ) is a histone deacetylase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Histone deacetylase inhibitor
Primary target: Histone deacetylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is belinostat?
belinostat (BELEODAQ) is a histone deacetylase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for belinostat?
BELEODAQ is a marketed brand name for belinostat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of belinostat?
belinostat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.